One Breakthrough Technology.
Two Potential Revenue Streams
We’re pioneering a potentially game-changing technology. LexaGene's MiQLab® is a rapid, automated pathogen detection system that can tap into multiple markets including: biopharma production and veterinary diagnostics. The revenue potential from penetration into these markets could be worth $600M+ annually1.
Top Three Reasons To Invest
Lack Of Timely Testing Can Cost Companies Millions
Biopharmaceutical manufacturers have to continually test their biopharma reactor line process for contaminants as the Food and Drug Administration prevents the distribution of products with detectable microbial contaminants. In some instances, these tests can take 14-28 days, resulting in the detection of contaminants late in the manufacturing process which can cost companies millions of dollars in wasted products. The earlier the contaminant is detected, the better the ability to limit the amount of loss.
Our Automated Tests Are 300X Faster2
MiQLab® is a rapid, fully automated contaminant and pathogen detection system for biopharma manufacturing. Our revolutionary testing system can detect most pathogens and biological contaminants in as little as 2 hours, helping companies detect contaminants early.
- Test 24 targets in a single sample
- Up to 1 minute hands-on time
- Results in 2 hours v. 28 days
Ready to learn more about how our technology works?
Major Biopharmas Have Already Performed Feasibility Studies of the MiQLab®
We’ve already performedexercises with two multi-billion dollar biopharma companies and have several systems in multiple veterinary care settings.
How We Can Ultimately Generate $400M-$600M in Annual Revenue
The annual total aggregate biopharma testing market is estimated to be $20B. The total veterinary diagnostic market is estimated to be $7.5B with full penetration into all testing. The initially targeted marketing segments could produce $100M of revenue opportunity. Earning just 2-3% market share represents a potential $400M-$600M total revenue opportunity for us1.
Multiple Growth Opportunities
We’re continuing to improve our MiQLab® technology. Our second generation MiQLab® will be able to test >95% of all bacteria and be even less costly for us to manufacture. Plus we aim to expand into multiple market verticals.
- Continue scaling in biopharma manufacturing
- Offer point-of-care testing in the veterinary market
- Seek FDA approval for human point-of-care testing, food testing, etc.
Ready to learn more about how our technology works?
Invest in $40M of Research at a Fraction of the Price
We’re on a mission to fully automate rapid molecular testing at the point-of-need to ultimately improve efficiencies in the biopharma industry and the overall health of our pets in the veterinary sector. Now we’re offering you the unique opportunity to join us. The cost of researching and developing this technology has totaled over $40M. Thanks to a strategic acquisition by Meridian, you’re able to invest at a significant discount to the cost of development alongside an experienced management team.
Invest Alongside a Veteran Management Team
We have a world-class management team with a proven track record of success in the molecular diagnostics industry. The creator of the technology, Dr. Jack Regan, is a highly respected scientist with over 20 years of experience in the field.
Tom Forte
Chief Executive Officer
Curt Boisfontaine
Chief Operating Officer, Board Member
David Ronck
Chief Financial Officer, Secretary, Board Member
Dr. Jack Regan
Founder/Chief Technology Officer, Board Member
Miles Blanton
Controller
Board Advisors & Consultants
Odis Pirtle
Board Advisor
Fletcher Spaght, Inc.
Biopharma Advisor/Consultant
Munsch Hardt Kopf & Harr, PC
Corporate Securities Counsel
Whitley Penn
Independent Auditor
FAQs
The MiQLab® System is a disruptive technology that has the potential to revolutionize the molecular diagnostics industry. It is significantly faster and more affordable than traditional PCR-based systems, making it more accessible to a wider range of users. LexaGene has a strong management team with a proven track record of success in the molecular diagnostics industry. The creator of the technology, Dr. Jack Regan, is a highly respected scientist with over 20 years of experience in the field.
Taking just 2% of a $15-$20B biopharma diagnostic market could be worth $400M-$600M in revenue annually. Plus they have more opportunities in the veterinary medicine space1.
Two biopharma manufacturers have already performed feasibility studies on the MiQLab system and continue to consider implementation.
They are still in the early stages of commercializing this breakthrough. Plus there is a future opportunity to expand into human medical diagnostics.
The development process for the technology is much more costly than initially contemplated. Replication is not easily done and their technology is patent protected. LexaGene has invested ~ $40 million developing this technology, an expensive endeavor. Meridian has acquired these LexaGene technology assets, licenses, patents, etc. at a significant discount to the investment to date in a distressed situation. Meridian’s investment to date is estimated to be ~ $7.5 million and expected to be $9.0 million by 12/31/23.
The shares of stock carry a liquidation preference - meaning the shares receive the first cash to be distributed to shareholders from operations or from a capital event in order to return the initial investment made by the shareholder. This liquidation preference results in shareholders receiving priority distributions before any other class of investor.
- Investing in startups is risky and there is no guarantee you will get a return on your investment. However, an exit opens up the opportunity where you could convert your shares into cash or a more liquid asset. Exits include going public, getting acquired by a larger company, or our company buying back shares. If the value of our company grows, then you have a higher potential of making a profit on your investment during one of these exits.
- You are investing in a pre-revenue company. Success will be measured in progress towards revenue. Future liquidation events could include acquisition or an IPO.
Shares will be awarded after the investment funds clear. This typically takes around 3 weeks after investment.
No, costs are the same, regardless of how you invest
No
As an investor, you are purchasing common stock of LexaGene Life Sciences CF Investors, Inc. which will make a capital investment in LexaGene Life Sciences, LLC in exchange for Class A Common Membership Units not to exceed 12.5% of total ownership.
Your Class A Common Membership Units provide you with a liquidation preference over other capital previously contributed to LexaGene Life Sciences. Meaning any cash generated by LexaGene Life Sciences, LLC, either from operations or from a capital event will FIRST go to repay all class A Common Membership Units initial investment before any other investors receive cash distributions.
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Individuals over 18 years of age can invest.
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
The Common Shares of LexaGene Life Sciences CF Investors, Inc. (the “Company”) are not publicly-traded. Neither are the membership interests of LexaGene Life Sciences, LLC. As a result, the Common Shares cannot be traded or sold in the first year after investment except as set forth below under the caption “Exceptions to limitations on selling shares during the one-year lockup period:" As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
Shares/Interests sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions. The exceptions are sales to:
(i) to the Company;
(ii) to an “accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act;
(iii) as part of an offering registered under the Securities Act with the SEC; or
(iv) to a member of the Investor’s family or the equivalent, to a trust controlled by the Investor, to a trust created for the benefit of a member of the family of the Investor or equivalent, or in connection with the death or divorce of the Investor or other similar circumstance.
In the event of death, divorce, or similar circumstance, shares can be transferred to:
- The company that issued the securities
- An accredited investor
- A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: invrelations@lexagenelifesciencs.com
At a minimum, the company will be filing with the SEC and posting on it’s website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.
